" class="no-js "lang="en-US"> Amit Kakar - Medtech Alert
Friday, April 19, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Amit Kakar

Amit Kakar

About Amit Kakar

Amit joined Novo Holdings Asia in August 2020 as Head of Asia to lead investments and partnerships across the region, focusing primarily on the markets in China, Japan, Singapore and Southeast Asia.

Amit has more than 25 years of healthcare experience with several senior management roles across the globe and having worked in India, China, Singapore and the USA. Previously, he has been with Everlife Asia based in Singapore as Head of M&A and Business Development, with the Avenue Capital Group as Head of healthcare investments for Asia and with GE Healthcare in several senior leadership positions.

Amit is a Medical Doctor with a postgraduate degree in Radiation and Nuclear Medicine from Tata Memorial Hospital and Cancer Centre in Mumbai, India .

Related Story

Cardiovascular

 Novo Holdings Leads $50 Million Investment in MedGenome to Accelerate Expansion Into New Markets and Deepen Product Offerings | Pharmtech Focus

Novo Holdings Leads $50 Million Investment in MedGenome to Accelerate Expansion Into New Markets and Deepen Product Offerings

August 30 2022

MedGenome, the leading genetic diagnostics, research, and data company in South Asia, announced today a […]